Linical Co., Ltd. announced that it has completed procedures for the establishment of a wholly owned subsidiary in Shanghai, China on 28 May 2019. The Linical group is advancing its global strategy by expanding its network and business overseas in the United States, Europe, and Asia in order to deliver a one-stop comprehensive service to the company's clients around the world. Linical has an affiliate company in Beijing, China since the acquisition of Accelovance Inc. last year. Linical Accelovance China Ltd. (Beijing, hereinafter "LAC") has been conducting business in China. LAC has been entrusted with several clinical trials from Japanese and European pharmaceutical companies. In order to respond to the increasing need for clinical trials in China and to enhance client satisfaction in speed, quality and convenience, Linical China Co., Ltd. has been established in Shanghai, China. Demand for clinical trials in China is expected to continue to increase. The establishment of Shanghai office, together with the existing Beijing office, expands the coverage to a wider range of business territory in China. The optimal organization structure in China will be examined in the medium to long term. Company name is Linical China Co., Ltd. Location is Room 31, 26F Lippo Plaza, 222 Middle Huaihai Road, Huangpu District, Shanghai, people's republic of China. Main business lines is CRO business. Establishment date is 28 May 2019.